FASN and neoplasm: Indeed, we have observed that ASO-LINC00842, which inhibits LINC00842, or Orlistat, which inhibits FASN activity, and combination of these two agents can significantly and synergistically repress PDAC growth and tumor burden in mouse xenograft and PDX models.